William Schwan

Office hours

Specialty area(s)

Pathogenic bacteriology, drug discovery and preclinical testing, uropathogenic Escherichia coli virulence/gene regulation, Staphylococcus aureus virulence/gene regulation

Current courses at UWL

Pathogenic Bacteriology (MIC 407/507)
Global Impact of Infectious Disease (MIC 130)
Mechanisms of Microbial Pathogenicity (454/554)

Professional history

My background is in bacterial pathogenesis and host responses to bacterial infections. I have worked with a variety of bacteria during my professional career.

I typically have 3-6 undergraduate students in my laboratory during the semester.

Several of my undergraduate students have been co-authors on peer-reviewed journal articles.

Research and publishing

Currently, I have three projects that I am working on:

1) Regulation of type 1 fimbriae in uropathogenic Escherichia coli
I use genetic, molecular, and animal models techniques to explore the regulation of this virulence factor.
2) Drug discovery/preclinical testing
I am collaborating with the Mycophyte Group at UW-L, Dr. James Cook at UW-Milwaukee, and Daniel Sem at Concordia University to try to bring new antibiotics through the pipeline.
3) Staphylococcus aureus drug persisters
This is a new area I am investigating that uses genetic, molecular, and animal models techniques to examine bacterial drug persisters.

List of Publications:

Schwan, W. R. and H. Ding**.  2017.  Temporal regulation of fim genes in uropathogenic Escherichia coli during infection of the murine urinary tract.  J. Pathogens 2017:8694356.

Schwan, W. R., R. Polanowski**, P. M. Dunman, S. Medina-Bielski*, M. Lane*, M. Rott, L. Lipker*, A. Wescott**, A. Monte, J. M. Cook, D. D. Baumann, V. V. N. Phani Babu Tiruveedhula, C. M. Witzigmann, C. Mikel*, and M. T. Rahman.  2017.  Identification of Staphylococcus aureus cellular pathways affected by the stilbenoid lead drug SK-03-92 using a microarray.  Antibiotics (Basel) 6:17.

Sweeney, N. L., L. Lipker*, A. M. Hanson, C. J. Bohl, K. E. Engel*, K. S. Kalous, M. E. Stemper, D. S. Sem, and W. R. Schwan.  2017.  Docking into Mycobacterium tuberculosis thioredoxin reductase protein yields pyrazolone lead molecules for methicillin-resistant Staphylococcus aureus.  Antibiotics (Basel)  6:1.

Schwan, W. R. , and K. J. Wetzel**. 2016. Osmolyte transport in Staphylococcus aureus . World J. Clin. Infect. Dis. 6:22-27.

Schwan, W. R. , J. M. Kolesar, M. S. Kabir, E. J. Elder Jr., J. B. Williams, R. Minerath**, J. M. Cook, C. M. Witzigmann, A. Monte, and T. Flaherty*. 2015. Pharmacokinetic/toxicity properties of the new anti-staphylococcal lead compound SK-03-92. Antibiotics 4:617-626.

Rentschler, A. E.**, S. D. Lovrich, and W. R. Schwan . 2013. OmpR regulation of the uropathogenic Escherichia coli fimB gene in an acidic/high osmolality environment. Microbiology 159:316-327.

Liu, X.-T., W. R. Schwan , T. J. Volk, M. A. Rott, M. Liu, P. Huang, Z. Liu, Y. Wang, N. C. Zitomer, C. Sleger*, S. Hartsel, A. P. Monte, and L. Zhang. 2012. Antibacterial spirobisnaphthalemnes from the North American cup fungus, Urnula craterium.  J. Nat. Prod. 75:1534-1538.

Schwan, W. R. 2012. Mushrooms: an untapped reservoir for antibacterial compounds. Curr. Topics Nutraceutical Res. 10:75-82.

Schwan, W. R. , M. S. Kabir, M. Kallaus*, S. Krueger*, A. Monte, and J. M. Cook. 2012. Synthesis and in vitro evaluation of SK-03-92, a new drug with activity against Staphylococcus aureus and other Gram-positive bacteria. J. Infect. Chemother. 18:124-126.

Schwan, W. R. 2011. Regulation of fim genes in uropathogenic Escherichia coli .
World J. Clin. Infect. Dis. 1:17-25.

Sharma, U., W. R. Schwan , and W. Agger. 2011. Myositis due to Escherichia coli in acute myelogenous leukemia. WMJ 110:182-184.

Wetzel, K. W.**, D. Bjorge*, and W. R. Schwan. 2011. Mutational and transcriptional analyses of the Staphylococcus aureus low affinity proline transporter OpuD during in vitro growth and infection of murine tissues. FEMS Immunol. Med. Microbiol. 61:346-355.

Shukla, S. K., M. E. Karow**, J. M. Brady, M. E. Stemper, J. Kislow, N. Moore*, K. Wroblewski*, P.-H. Chyou, D. M. Warshauer, K. D. Reed, R.Lynfield, and W. R. Schwan. 2010. Virulence genes and genotypic associations in community-associated methicillin-resistant and susceptible Staphylococcus aureus.  J. Clin. Microbiol. 48:3582-3592.

Schwan, W. R. , C. Dunek*, M. Gebhardt*, K. Engelbrecht**, T. Klett*, A. Monte, J. Toce, M. Rott, T. J. Volk, J. J. LiPuma, X. T. Liu, and R. McKelvey. 2010. Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity. Ann. Clin. Microbiol. Antimicrob. 9:4.

Liu, X.-T., A. L.Winkler*, W. R. Schwan , T. J. Volk, M. A. Rott, and A. Monte. 2010. Antibacterial compounds from mushrooms I: a lanostane-type triterpene and prenylphenol derivatives from Jahnoporus hirtus and Albatrellus flettii and their activities against Bacillus cereus and Enterococcus faecalis . Planta Med. 76:182-185.

Liu, X. T., A. L.Winkler*, W. R. Schwan , T. J.Volk, M. Rott, and A. Monte. 2010. Antibacterial compounds from mushrooms II: lanostane triterpenoids and an ergostane steroid with activity against Bacillus cereus isolated from Fomitopsis pinicola . Planta Med. 76:464-466.

Schwan, W. R. , A. Briska, B. Stahl, T. K. Wagner, E. Zentz, J. Henkhaus, S. D. Lovrich, W. A. Agger, S. M. Callister, B. DuChateau, and C. W. Dykes. 2010. Use of optical mapping to sort uropathogenic Escherichia coli strains into distinct subgroups. Microbiology 156:2124-2135.

Kabir, M. S., O. A. Namjoshi , R. Verma, R. Polanowski*, S. M. Krueger*,
D. Sherman, M. A. Rott, W. R. Schwan , A. Monte, and J. M. Cook. 2010. A new class of potential anti-tuberculosis agents: synthesis and preliminary evaluation of novel acrylic acid ethyl ester derivatives. Bioorg. Med. Chem. 18:4178-4186.

* = Undergraduate student
** = Graduate student


B. S. - Quincy College
M. S. - Iowa State university
Ph.D. - Northwestern University
Postdoc - University Wurzburg
Postdoc - FDA